Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + ibrutinib vs rituximab + chemotherapy in older patients with untreated mantle cell lymphoma
2015-000832-13Phase 2Unknown
- Sponsor
- University Hospitals Plymouth
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by University Hospitals Plymouth. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2015-000832-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000832-13.